Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.
Skip to main content

PSMA-PET is changing how we stage prostate cancer, both in the primary setting and with relapse after treatment. It allows us to identify lesions in the bones and lymph nodes that were not previously visible on conventional imaging with bone scan and CT/MRI. In this Special Report we review the 'state of the art' for PSMA imaging and discuss the implications for treatment decisions in prostate cancer. We liken early high risk or metastatic prostate to a common phytological problem: the dandelion. In this analogous situation, we consider the additional evidence needed for us to start plucking out the original dandelion and for us to focus attention on killing the seeded weeds that are identifiable elsewhere in the lawn.

Original publication

DOI

10.2217/fon-2017-0074

Type

Journal article

Journal

Future Oncol

Publication Date

08/2017

Volume

13

Pages

1801 - 1807

Keywords

PET, PSMA, metastasis, prostate cancer, staging, Antigens, Surface, Bone Neoplasms, Glutamate Carboxypeptidase II, Humans, Male, Molecular Imaging, Neoplasm Metastasis, Neoplasm Staging, Positron Emission Tomography Computed Tomography, Positron-Emission Tomography, Prostatic Neoplasms, Tomography, X-Ray Computed